FDA Approves Priteliver for Refractory Herpes Infections
The US FDA has approved pritelivir for refractory herpes infections, giving dermatologists a new option for patients who fail standard antiviral therapy.
Topic
FDA Approval
Topic
FDA Approval
FDA Approves 8-Week Maintenance Dosing for EBGLYSS in Atopic Dermatitis
Eli Lilly's EBGLYSS label update from the FDA allows one subcutaneous maintenance dose every eight weeks for adults with moderate…
Rhapsido Becomes First FDA-Approved Therapy for Symptomatic Dermographism
Novartis' Rhapsido (remibrutinib) became the first FDA-approved therapy for symptomatic dermographism, extending its reach beyond…
FDA Expands Urticaria Drug Indication to Symptomatic Dermographism
The FDA has expanded a urticaria drug's indication to treat symptomatic dermographism, moving a common inducible urticaria into o…
FDA Approves Light-Based Therapy for a Common Skin Cancer
The FDA has approved a light-based treatment for a common skin cancer, adding a nonsurgical phototherapy option for non-melanoma…
FDA Approves RHA Redensity Eye for Infraorbital Hollowing
The FDA has approved RHA Redensity Eye, a hyaluronic acid-based injectable, for the treatment of under-eye hollows. The action ex…
FDA Approves Therapy MedPage Calls a 'Potential Game Changer' for Psoriasis
The FDA has green-lit a psoriasis therapy that MedPage Today calls a "potential game changer" — a signal specialists see as more…
FDA Approves Remibrutinib for Symptomatic Dermographism
The US FDA has approved oral BTK inhibitor remibrutinib for symptomatic dermographism, delivering the first labeled targeted ther…
FDA Approves Icotrokinra, First Oral Targeted Peptide for Plaque Psoriasis
The FDA has approved icotrokinra, the first oral targeted peptide for plaque psoriasis, adding a new formulation category to the…
FDA Approves Icotrokinra, First Targeted Oral Peptide for Plaque Psoriasis
FDA approves icotrokinra, the first targeted oral peptide for moderate-to-severe plaque psoriasis, expanding systemic options bey…